UCB’s Cimzia shows efficacy against plaque psoriasis

UCB has announced new clinical trial data that demonstrates the benefits its drug Cimzia can offer in the treatment of chronic plaque psoriasis.

Topline results have been announced from CIMPASI-2, a phase III multicentre placebo-controlled clinical trial, which evaluated the efficacy and safety of Cimzia in adult patients with moderate to severe chronic plaque psoriasis.

It was shown that Cimzia demonstrated statistically significant improvements for both co-primary endpoints at both treatment doses, with better rates of disease improvement and skin clarity compared to placebo after 16 weeks.

The CIMPASI-2 trial results are from the first of three phase III clinical trials to be reported evaluating Cimzia in this patient population.

Emmanuel Caeymaex, head of the immunology patient value unit at UCB, said: "Psoriasis has historically been difficult to treat and there remains a high unmet need among these patients, who still need additional treatment alternatives."

Cimzia is indicated for the treatment of adults with rheumatoid arthritis, Crohn's disease, psoriatic arthritis and ankylosing spondylitis. It has not yet been approved as a psoriasis therapy in any country.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.